Astellas' Astagraf XL Launched in U.S. - Analyst Blog NASDAQ Astagraf XL was approved in the U.S. in Jul 2013 for the prophylaxis of organ rejection in patients receiving a kidney transplant used with mycophenolate mofetil (MMF) and corticosteroids, with or without basiliximab induction. As per Astellas ... ASTELLAS PHARMA INC : ASTAGRAF XLTM (tacrolimus extended-release ... Astellas Pharma launches once-daily oral tacrolimus formulation in US |
